Hikma Pharmaceuticals (HKMPF)
(Delayed Data from OTC)
$25.70 USD
0.00 (0.00%)
Updated Sep 13, 2024 02:56 PM ET
2-Buy of 5 2
A Value A Growth F Momentum A VGM
Balance Sheet
Fiscal Year End for Hikma Pharmaceuticals Plc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 205 | 270 | 426 | 327 | 443 |
Receivables | 873 | 841 | 876 | 792 | 798 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 891 | 776 | 695 | 757 | 568 |
Other Current Assets | 131 | 112 | 97 | 46 | 39 |
Total Current Assets | 2,100 | 1,999 | 2,094 | 1,922 | 1,848 |
Net Property & Equipment | 1,096 | 1,024 | 1,072 | 1,009 | 912 |
Investments & Advances | 113 | 75 | 57 | 48 | 43 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 226 | 192 | 183 | 221 | 243 |
Intangibles | 1,100 | 1,124 | 892 | 876 | 834 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 4,680 | 4,471 | 4,372 | 4,135 | 3,930 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 568 | 476 | 468 | 470 | 473 |
Current Portion Long-Term Debt | 150 | 139 | 112 | 158 | 569 |
Current Portion Capital Leases | 11 | 9 | 9 | 10 | 9 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 74 | 73 | 57 | 72 | 82 |
Other Current Liabilities | 536 | 380 | 370 | 318 | 338 |
Total Current Liabilities | 1,339 | 1,077 | 1,016 | 1,028 | 1,471 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 25 | 19 | 24 | 31 | 20 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 975 | 1,074 | 651 | 692 | 48 |
Non-Current Capital Leases | 55 | 61 | 74 | 72 | 59 |
Other Non-Current Liabilities | 77 | 92 | 140 | 164 | 203 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 2,471 | 2,323 | 1,905 | 1,987 | 1,801 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 40 | 40 | 42 | 41 | 41 |
Capital Surplus | 282 | 282 | 282 | 282 | 282 |
Retained Earnings | 2,158 | 2,092 | 2,189 | 1,892 | 1,973 |
Other Equity | -271 | -266 | -46 | -67 | -167 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 2,209 | 2,148 | 2,467 | 2,148 | 2,129 |
Total Liabilities & Shareholder's Equity | 4,680 | 4,471 | 4,372 | 4,135 | 3,930 |
Total Common Equity | 2,209 | 2,148 | 2,467 | 2,148 | 2,129 |
Shares Outstanding | 220.20 | 220.20 | 242.30 | 242.30 | 242.30 |
Book Value Per Share | 10.03 | 9.75 | 10.18 | 8.87 | 8.79 |
Fiscal Year End for Hikma Pharmaceuticals Plc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | -99,999 | 205 | -99,999 | -99,727 |
Receivables | NA | NA | 873 | NA | 905 |
Notes Receivable | NA | NA | 0 | NA | NA |
Inventories | NA | NA | 891 | NA | 859 |
Other Current Assets | NA | NA | 131 | NA | 140 |
Total Current Assets | NA | NA | 2,100 | NA | 2,176 |
Net Property & Equipment | NA | NA | 1,096 | NA | 1,032 |
Investments & Advances | NA | NA | 113 | NA | 72 |
Other Non-Current Assets | NA | NA | 0 | NA | NA |
Deferred Charges | NA | NA | 226 | NA | 200 |
Intangibles | NA | NA | 1,100 | NA | 1,084 |
Deposits & Other Assets | NA | NA | 0 | NA | NA |
Total Assets | NA | NA | 4,680 | NA | 4,619 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | NA | 0 | NA | NA |
Accounts Payable | NA | NA | 568 | NA | 505 |
Current Portion Long-Term Debt | NA | NA | 150 | NA | 211 |
Current Portion Capital Leases | NA | NA | 11 | NA | 10 |
Accrued Expenses | NA | NA | 0 | NA | NA |
Income Taxes Payable | NA | NA | 74 | NA | 73 |
Other Current Liabilities | NA | NA | 536 | NA | 416 |
Total Current Liabilities | NA | NA | 1,339 | NA | 1,215 |
Mortgages | NA | NA | 0 | NA | NA |
Deferred Taxes/Income | NA | NA | 25 | NA | 26 |
Convertible Debt | NA | NA | 0 | NA | NA |
Long-Term Debt | NA | NA | 975 | NA | 1,032 |
Non-Current Capital Leases | NA | NA | 55 | NA | 59 |
Other Non-Current Liabilities | NA | 77 | NA | 85 | |
Minority Interest (Liabilities) | NA | NA | 0 | NA | NA |
Total Liabilities | NA | NA | 2,471 | NA | 2,417 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | NA | 0 | NA | NA |
Common Stock (Par) | NA | NA | 40 | NA | 40 |
Capital Surplus | NA | NA | 282 | NA | 282 |
Retained Earnings | NA | NA | 2,158 | NA | 2,146 |
Other Equity | NA | NA | -271 | NA | -266 |
Treasury Stock | NA | NA | 0 | NA | NA |
Total Shareholder's Equity | NA | NA | 2,209 | NA | 2,202 |
Total Liabilities & Shareholder's Equity | NA | NA | 4,680 | NA | 4,619 |
Total Common Equity | 0 | 0 | 2,209 | 0 | 102,201 |
Shares Outstanding | 220.20 | 220.20 | 220.20 | 220.20 | 220.20 |
Book Value Per Share | 0.00 | 0.00 | 10.03 | 0.00 | 464.13 |